肿瘤靶向药物相关皮肤不良反应及发生机制
Cutaneous adverse reactions associated with targeted cancer therapy and its pathogenesis
摘要
Abstract
In recent years,targeted cancer therapy has developed rapidly and have become one of the most important choices for cancer treatment.While they exert anti-tumor effects,they may also damage the function of normal tissues,among which cutaneous adverse reactions are the most common.Some cutaneous ad-verse reactions severely affect patients'quality of life,lead to poor treatment compliance and ultimately affect the long-term survival.Therefore,a proper understanding of the cutaneous adverse reactions and its pathogene-sis related to targeted cancer therapy can help guide future mechanism-based diagnosis and treatment,thus im-prove patients'quality of life.关键词
肿瘤靶向药物/皮肤不良反应/表皮生长因子受体/血管内皮生长因子受体/BRAF/免疫检查点抑制剂Key words
targeted cancer therapy/cutaneous adverse reaction/epidermal growth factor receptor/vascular endothelial growth factor receptor/BRAF/immune checkpoint inhibitor引用本文复制引用
邓姝婷,姚煦..肿瘤靶向药物相关皮肤不良反应及发生机制[J].中华临床免疫和变态反应杂志,2024,18(2):181-189,9.基金项目
国家重点研发计划项目(2022YFC3601800) （2022YFC3601800）
国家自然科学基金资助项目(82073446,82103735) （82073446,82103735）
江苏省社会发展重大项目(BE2020632) （BE2020632）
中国医学科学院医学与健康科技创新工程项目(2021-I2M-1-059) （2021-I2M-1-059）
南京市国家级临床医学中心培育计划项目(2019060001) （2019060001）
中国医学科学院中央级公益性科研院所基本科研业务费专项资金项目(2021-RC320-001,2020-RC320-003) National Key R&D Program of China(2022YFC3601800) （2021-RC320-001,2020-RC320-003）
National Natural Science Foundation of China(82073446,82103735) （82073446,82103735）
Key Project of Social Development in Jiangsu Province(BE2020632) （BE2020632）
CAMS Innovation Fund for Medical Sciences(2021-I2M-1-059) （2021-I2M-1-059）
Nanjing Incubation Program for National Clinical Research Center(2019060001) （2019060001）
Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences(2021-RC320-001,2020-RC320-003) （2021-RC320-001,2020-RC320-003）
